ROGER S LO, M.D.
Dermatology at Sawtelle Blvd, Los Angeles, CA

License number
California A84131
Category
Medical Practice
Type
Specialist
License number
California A84131
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
1950 Sawtelle Blvd STE 145, Los Angeles, CA 90025
Phone
(310) 575-4050
(310) 575-4250 (Fax)

Personal information

See more information about ROGER S LO at radaris.com
Name
Address
Phone
Roger Lo
722 W Graves Ave, Monterey Park, CA 91754
(626) 673-2474
Roger Lo
6237 N Muscatel Ave, San Gabriel, CA 91775
(626) 287-9966
Roger Lo
5418 E Flagstone St, Long Beach, CA 90808
(562) 493-1946
Roger Lo
2362 Cuatro Dr, Rowland Heights, CA 91748
(626) 839-6026
Roger Lo
2340 Ohio Dr, Claremont, CA 91711
(909) 625-2803

Professional information

Roger Lo Photo 1

Re/Max Masters

Position:
Broker Associate, Investment Specialist at RE/MAX Masters, Computer Consultant at Computer Consulting
Location:
Greater Los Angeles Area
Industry:
Real Estate
Work:
RE/MAX Masters - Greater Los Angeles Area since Dec 2012 - Broker Associate, Investment Specialist Computer Consulting since Aug 2005 - Computer Consultant
Education:
CSUSB
BA, Information Management
Nippon Electronic College
Certificate, Computer Science
Interests:
Golf and most sports


Roger Lo Photo 2

Roger Lo

Position:
Assistant Professor at Cailfornia State University, Long Beach
Location:
Greater Los Angeles Area
Industry:
Research
Work:
Cailfornia State University, Long Beach since Aug 2009 - Assistant Professor
Education:
Texas A&M University 2002 - 2008
Texas A&M University 2000 - 2002
National Chung Hsing University 1993 - 1997
Skills:
Data Analysis, Chromatography, Microscopy, Chemistry, Chemical Engineering, Biotechnology, R&D, Science, Research, Microfluidics, Matlab


Roger S Lo Photo 3

Dr. Roger S Lo, Los Angeles CA - MD (Doctor of Medicine)

Specialties:
Dermatology
Address:
1950 Sawtelle Blvd, Los Angeles 90025
(310) 575-4050 (Phone), (310) 575-4250 (Fax)
200 Medical Plz Way, Los Angeles 90095
(310) 917-3376 (Phone)
Nippon Medical Clinic
1950 Sawtelle Blvd SUITE 145, Los Angeles 90025
(310) 575-4050 (Phone)
1131 Wilshire Blvd, Santa Monica 90401
(310) 817-3376 (Phone)
Certifications:
Dermatology, 2007
Awards:
Healthgrades Honor Roll
Languages:
English, Mandarin, Spanish
Education:
Medical School
Joan Sanford I Weill Medical College Of Cornell University
Graduated: 2002
Ny Med College
UCLA Med Ctr/UCLA D Geffen School


Roger Lo Photo 4

Assistant Professor At Ucla

Position:
Assistant Professor at UCLA
Location:
Greater Los Angeles Area
Industry:
Medical Practice
Work:
UCLA - Assistant Professor
Education:
Stanford University


Roger Sheng-Chieh Lo Photo 5

Roger Sheng-Chieh Lo, Los Angeles CA

Specialties:
Dermatology
Work:
Roger Lee
200 Peter Morton Medical, Los Angeles, CA UCLA Medical Center
10833 Le Conte Ave, Los Angeles, CA 90095 UCLA Medical Center
200 Ucla Medical Plz, Los Angeles, CA 90095
Education:
Cornell University (2002)


Roger Shengchieh Lo Photo 6

Roger Shengchieh Lo, Los Angeles CA

Specialties:
Dermatologist
Address:
1950 Sawtelle Blvd, Los Angeles, CA 90025
Education:
Doctor of Medicine
Board certifications:
American Board of Dermatology Certification in Dermatology


Roger Lo Photo 7

Compositions And Methods For Detection And Treatment Of B-Raf Inhibitor-Resistant Melanomas

US Patent:
2013021, Aug 22, 2013
Filed:
Nov 18, 2011
Appl. No.:
13/879302
Inventors:
Roger S. Lo - Los Angeles CA, US
Antoni Ribas - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/574, A61K 31/437, A61K 45/06, C12Q 1/68
US Classification:
514300, 435 612, 435 79, 506 9
Abstract:
Specific, targetable molecules mediating acquired resistance of B-RAF-mutant melanomas to a B-RAF inhibitor, thereby providing materials and methods for the treatment and detection of B-RAF inhibitor resistant cancers, such as melanoma. A method of identifying a patient to be treated with an alternative to B-RAF inhibitor therapy is described. Also described is a method of treating a patient having cancer. The patient is administered a MEK inhibitor, optionally in conjunction with vemurafenib therapy, or an inhibitor of the MAPK pathway (RAF, MEK, ERK) in conjunction with an inhibitor of the RTK-PI3K-AKT-mTOR pathway.